Decoding multifocal hepatocellular carcinoma: an opportune pursuit.
1Department of Medicine, VA Boston Healthcare System and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02130, USA.
Hepatobiliary Surgery and Nutrition
|July 8, 2015
Summary
Distinguishing multiple hepatocellular carcinoma (HCC) origins is crucial for treatment. A new study identifies TTK as a biomarker predicting aggressive behavior and recurrence in HBV-related HCC patients.
Area of Science:
- Hepatology
- Oncology
- Genomics
Background:
- Hepatocellular carcinoma (HCC) is a prevalent cancer with poor prognosis, often diagnosed as multiple tumors.
- Multiple HCC can arise from multicentric occurrence (MO-HCC) or intrahepatic metastases (IM-HCC), necessitating accurate differentiation for effective management.
Purpose of the Study:
- To differentiate the clonality of MO-HCC versus IM-HCC using a multi-omics approach.
- To identify key parameters linking clonality to tumor behavior and prognosis in HBV-related HCC.
Main Methods:
- Multi-omics analysis integrating genomic and clinical data.
- Comparative analysis of tumor clonality in MO-HCC and IM-HCC patient cohorts.
- Biomarker identification for predicting HCC behavior and recurrence.
Main Results:
- Identification of distinct molecular signatures differentiating MO-HCC and IM-HCC.
- The mitotic checkpoint regulator TTK emerged as a significant biomarker.
- TTK expression levels correlated with aggressive tumor behavior and early postoperative recurrence.
Conclusions:
- Reliable distinction between MO-HCC and IM-HCC is clinically vital.
- TTK is a promising novel biomarker for predicting HCC aggressiveness and recurrence in HBV-related cases.
- This research provides insights for optimizing treatment strategies for multiple HCC.
